Research
Hormonal
Weekly subcutaneous tirzepatide (5-15 mg) produces significant, dose-dependent weight loss (-15% to -21%) and improves cardiometabolic markers in adults with overweight/obesity, including those with type 2 diabetes.
If you have obesity or overweight with related health issues, weekly tirzepatide injections, combined with diet and exercise, can lead to significant weight loss (15-21%) and improve heart and metabolic health. Start with a low dose to minimize side effects, and gradually increase it as tolerated.
StrongSupportsHIGH confidence
Рандомизированное клиническое исследование SURMOUNT-1 показало, что применение тирзепатида у пациентов с ИзМТ и ожирением без СД 2 типа вызывает значительную дозозависимую потерю массы тела (-15,0% ... при еженедельных дозах тирзепатида 5 мг, -19,5% ... при дозах 10 мг и -20,9% ... при дозах 15 мг).
Why this rating
Based on a cited randomized clinical trial (SURMOUNT-1) and meta-analyses.
Source
Overweight and obesity in metabolic syndrome
С. В. Недогода et al. · Russian Journal of Cardiology · 2025
DOI 10.15829/1560-4071-2025-6535
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Weekly subcutaneous semaglutide (2.4 mg) produces significant weight loss (-10%) and improves cardiometabolic markers in adults with overweight/obesity, including those with type 2 diabetes.Strong
- Weekly subcutaneous liraglutide (3.0 mg) produces significant weight loss (-5.24 kg) and improves cardiometabolic markers in adults with overweight/obesity, though it is less effective than semaglutide 2.4 mg.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →